BFH772 (VEGFR2 inhibitor): Technical Guidance and Application Notes

What This Product Solves

BFH772 is a potent, small-molecule VEGFR2 inhibitor designed for precise disruption of VEGFR2-mediated angiogenic pathways. Its high selectivity (IC50: 3 nM for VEGFR2) and approximately 500-fold lower potency against related receptors (FLK-1, FLT-1, FLT-4) make it an effective tool for delineating VEGFR2-specific signaling in angiogenesis and tumor growth research (product_spec). This compound addresses the need for targeted inhibition without significant off-target effects common to less selective kinase inhibitors. Researchers investigating tumor angiogenesis, VEGFR2 pathway dynamics, or the effects of anti-angiogenic agents in preclinical models will find BFH772 suitable for applications requiring high pathway specificity.

Protocol Parameters

• in vitro VEGFR2 kinase assay | IC50 = 3 nM | Use for dose-response studies requiring high sensitivity to VEGFR2 | Enables precise measurement of VEGFR2 signaling inhibition; minimizes confounding kinase activity | product_spec
• solvent compatibility | ≥53.4 mg/mL (DMSO), ≥15.33 mg/mL (ethanol), insoluble in water | Use in protocols compatible with DMSO or ethanol as solvents | Ensures BFH772 remains in solution; critical for consistent dosing and assay reproducibility | product_spec
• storage temperature | -20°C | Use for all long-term storage of solid compound | Preserves chemical stability and purity; avoid repeated freeze-thaw cycles | product_spec
• solution stability | Short-term use only (do not store solutions long-term) | Prepare fresh working solutions for each experiment | Reduces risk of compound degradation and assay variability | product_spec

Workflow Setup and QC Checklist

For optimal results with BFH772 in angiogenesis or tumor model research, adhere to these workflow best practices:

• Compound Preparation: Dissolve BFH772 in DMSO or ethanol to achieve the desired concentration. Avoid water-based solvents due to insolubility (product_spec).
• Solution Freshness: Prepare working solutions immediately before use. Discard any unused solution after each session to prevent activity loss.
• Concentration Range: For in vitro inhibition studies, begin with low nanomolar concentrations and titrate upwards based on observed effects and cell/tissue system sensitivity.
• Storage Practices: Store the solid compound at -20°C in a desiccated environment. Refrain from multiple freeze-thaw cycles to maintain purity and activity.
• Quality Control: Confirm batch purity (>96%) and reference the provided certificate of analysis and safety data sheet.

For more detailed setups and troubleshooting, see BFH772 (VEGFR2 inhibitor): Technical Use & Protocol Parameters, which outlines additional workflow recommendations and cautions for water-insoluble compounds.

Common Failure Modes and Fixes

• Incomplete Dissolution: If BFH772 does not dissolve fully, verify solvent quality and concentration limits (≥53.4 mg/mL DMSO, ≥15.33 mg/mL ethanol). Use brief sonication or gentle warming if necessary, but avoid excessive heat that could degrade the compound.
• Loss of Activity in Solution: If inhibition efficacy decreases, ensure that fresh solutions are prepared for each experiment and that storage guidelines are strictly followed. Never store diluted solutions for extended periods (product_spec).
• Unexpected Off-Target Effects: While selectivity is high, confirm that observed effects are VEGFR2-specific by including appropriate controls, given that residual activity against B-RAF, RET, and TIE-2 is possible at higher concentrations.
• Precipitation in Aqueous Media: Since BFH772 is insoluble in water, always add the compound to culture media slowly and with adequate mixing to avoid precipitation. Ensure final DMSO or ethanol concentrations are compatible with your biological system.

Expanded troubleshooting protocols are detailed in BFH772 (VEGFR2 inhibitor): Technical Guidance & Protocol Setup, which focuses on maximizing selectivity and addressing common solubility issues in VEGFR2 pathway research.

Scope and Limitations

• Intended Use: BFH772 should be applied in studies where selective VEGFR2 pathway inhibition is required, particularly for dissecting angiogenesis mechanisms in vitro or in tumor model systems (product_spec).
• Solubility Constraints: Do not use BFH772 in workflows requiring water-soluble compounds; alternative inhibitors should be sought for such applications.
• Broad Kinase Inhibition: Due to its high specificity, BFH772 is unsuitable for studies where broad or pan-kinase inhibition is needed.
• Clinical Use: This compound is for research use only; no clinical dosing or patient applications are supported by the product dossier.

Conclusion

BFH772 (VEGFR2 inhibitor) is a targeted research tool for precise modulation of VEGFR2 signaling in angiogenesis and tumor growth models. Its selectivity and potency make it preferable when off-target kinase activity would confound results. Researchers should strictly observe solubility and storage recommendations, use the compound only in DMSO or ethanol-compatible workflows, and reference product quality documentation before use. For further protocol guidance and troubleshooting, consult the linked technical resources.